Skip to content
Menu

Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $170 Price Target

Benzinga Newsdesk 18 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.

Cantor Fitzgerald analyst Kristen Kluska reiterates Disc Medicine (NASDAQ:IRON) with a Overweight and maintains $170 price target.

Read at benzinga.com